Teleflex to Showcase its Peripheral Intervention Product Portfolio Highlighting the Arrow® OnControl® Powered Bone Access System and the MANTA ™ Vascular Closure Device at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2019

August 30, 2019

WAYNE, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will showcase its Peripheral Intervention product portfolio including the Arrow® OnControl® Powered Bone Access System and the MANTA ™ Vascular Closure Device at the CIRSE being held in Barcelona, Spain on September 07 – 11, 2019.

As the interventional cornerstone of Teleflex, we offer a growing portfolio of specialty-focused solutions to support interventionalists around the globe. Our products are known for their innovative ability to simplify complex procedures and common clinical challenges. Interventionalists worldwide rely on our innovative solutions, such as the MANTA™ Device, the OnControl® System, the Hunter™ Biopsy Sealing Device, the Arrow-Clark™ VectorFlow® Chronic Hemodialysis Catheter™, the Turnpike® Catheter, the SuperCross® Microcatheter, Super Arrow-Flex® Sheaths and Pronto® Extraction Catheters.

The CE Marked MANTA ™ Vascular Closure Device is specifically designed for closure of large bore femoral arteriotomies following procedures utilizing devices or sheaths ranging in size from 10F to 18F (with maximum outer diameters up to 25F). The SAFE MANTA IDE Clinical Trial demonstrated that the median time from deployment to hemostasis was 24 seconds (65 second mean time).[1a] Technical success was achieved in 97.7% of patients, and a single device was deployed in 99.6% of cases.[1b] The IDE-defined major complications[1c], the primary safety end point for the study, occurred in 5.3% of patients and Valve Academic Research Consortium-2 (VARC-2) major vascular complications occurred in 4.2% of cases.[1] This VARC-2 rate is lower than published rates for suture-mediated closure.[2,3]

Teleflex will be running two Hands-on Device Training Sessions during the congress:

- Vertebral Augmentation on Tuesday, September 10 (VA-HDT 1 from 09:30 to 11:00 & VA-HDT 2 from 12:30 to 14:00) where we will showcase our OnControl® System
- A closer look at closure devices on Saturday, September 7 (CD-HDT 1 from 09:30 to 11:00 & CD-HDT 2 from 12:30 to 14:00) where we will showcase the MANTA ™ Vascular Closure Device

Clinicians worldwide rely on the quality and proven clinical utility of our peripheral intervention portfolio.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people's lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

References:
1. Wood D, et al. Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device: The SAFE MANTA Study. Circulation: Cardiovascular Interventions. 2019 July. Vol 12, Issue 7.
a. MANTA™ Device demonstrated a time to hemostasis of 24 seconds median time (65 seconds mean time) from deployment to hemostasis.
b. Percutaneous vascular closure obtained with the MANTA™ Device without the use of unplanned endovascular or surgical intervention.
c. Major complications defined as composite of i) vascular injury requiring surgical repair/stent-graft; ii) bleeding requiring transfusion; iii) lower extremity ischemia requiring surgical repair/additional percutaneous intervention; iv) nerve injury (permanent or requiring surgical repair); and v) infection requiring IV antibiotics and/or extended hospitalization.
Study sponsored by Teleflex Incorporated or its affiliates.
2. Généreux P, et al. Vascular complications after transcatheter aortic valve replacement. J Am Coll Cardiol. 2012 Sept 18;60(12):1043-1052.
3. Lauten A, et al. Percutaneous left-ventricular support with the Impella 2.5®-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail. 2013 Jan;6(1):23-30.

Source:
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836

Source: Teleflex Incorporated